To PEGylate or Not To PEGylate Therapeutics?

Keith E Maier; Christopher P Rusconi; Matthew Levy

doi:10.1016/j.chembiol.2019.04.014

To PEGylate or Not To PEGylate Therapeutics?

Cell Chem Biol. 2019 May 16;26(5):615-616. doi: 10.1016/j.chembiol.2019.04.014.

Authors

Keith E Maier¹, Christopher P Rusconi¹, Matthew Levy²

Affiliations

¹ Vitrisa Therapeutics, Inc., Durham, NC 27701, USA.
² Vitrisa Therapeutics, Inc., Durham, NC 27701, USA. Electronic address: mlevy@vitrisatherapeutics.com.

PMID: 31100258
DOI: 10.1016/j.chembiol.2019.04.014

Abstract

PEGylation is a common modulator of pharmacokinetics for therapeutic agents in vivo. In this issue of Cell Chemical Biology, Moreno et al. (2019) show anti-PEG antibodies may directly inhibit the activity of a PEGylated aptamer, RB006, both in vitro and in vivo, and the issues surrounding anti-PEG antibodies are discussed.

Publication types

Comment

MeSH terms

Anticoagulants
Oligonucleotides*
Polyethylene Glycols*

Substances

Anticoagulants
Oligonucleotides
Polyethylene Glycols